Key Takeaways
- UCB acquires Candid Therapeutics for up to $2.2 billion, including $2.0 billion upfront.
- Two River and Vida Ventures played key roles in founding and developing Candid, focusing on innovative autoimmune therapies.
- The acquisition reflects a successful collaboration within the Bellco Health ecosystem to advance biotechnology innovations.
Two River, LLC and Vida Ventures, integral parts of the Bellco Health ecosystem, have acknowledged the acquisition of Candid Therapeutics by UCB, a global biopharmaceutical company, for up to $2.2 billion. This transaction includes $2.0 billion upfront and positions Candid as a leader in treating autoimmune and inflammatory diseases through cutting-edge T-cell engagers (TCEs).
Two River, along with Third Rock Ventures, was instrumental in founding Candid, showcasing a commitment to scaling innovative biotech firms. Candid emerged from a merger between TRC 2004—a company established by Two River—and Vignette Bio. This merger leveraged complementary strengths and established a management team with extensive experience in autoimmune TCE therapies. Through TRC 2004, Two River successfully sourced one of Candid’s leading assets from China, demonstrating its ability to harness global innovation effectively.
Vida Ventures invested in Candid as part of its strategy to support high-quality entrepreneurs and promising assets, having a solid track record of facilitating companies through critical scientific milestones.
Dr. Arie Belldegrun, Co-Founder of Bellco and Chairman of Two River, remarked, “This outcome reflects the power of bold science, disciplined company building, and the right strategic partners.” He emphasized the focus on incubating transformative ideas at Two River and nurturing them through critical phases at Vida. Joshua Kazam, a Partner at Two River, echoed that Candid embodies the type of company they aim to build, driven by distinctive biology that holds the potential to redefine treatment approaches.
The trajectory of Candid highlights the ongoing momentum within the Bellco ecosystem, where collaborative efforts streamline company creation, early investments, and strategic partnerships to accelerate innovation. Two River’s model supports firms from inception through critical value-defining milestones, reinforcing its position as a repeatable company creation engine.
Vida Ventures recently completed a productive year, achieving significant milestones with several M&A transactions and successful IPOs, highlighting a robust appetite from investors for innovative science. These developments emphasize Vida’s multi-pillar investment strategy, which blends scientific expertise with disciplined capital management to thrive across the life sciences landscape.
Two River is known for building innovative biotechnology companies focused on addressing unmet medical needs. Meanwhile, Vida Ventures, founded by Dr. Arie Belldegrun, combines scientists, physicians, and investors to propel advancements in biomedicine, maintaining approximately $1.8 billion in capital commitments aimed at fostering groundbreaking innovations.
The content above is a summary. For more details, see the source article.